- Home
- Publications
- Publication Search
- Publication Details
Title
Recent developments in the treatment of inflammatory bowel disease
Authors
Keywords
-
Journal
Journal of Digestive Diseases
Volume 14, Issue 6, Pages 282-287
Publisher
Wiley
Online
2013-02-20
DOI
10.1111/1751-2980.12048
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
- (2015) B.G. Feagan et al. GASTROENTEROLOGY
- 943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC
- (2015) W.J. Sandborn et al. GASTROENTEROLOGY
- One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
- (2012) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study
- (2012) William J. Sandborn et al. GASTROENTEROLOGY
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
- (2012) Axel Dignass et al. Journal of Crohns & Colitis
- Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: A meta-analysis
- (2012) Jin Lu TONG et al. Journal of Digestive Diseases
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
- (2011) Nicholas J Talley et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
- (2011) Cosimo Prantera et al. GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- New therapies for inflammatory bowel disease: from the bench to the bedside
- (2011) Silvio Danese GUT
- The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
- (2011) S. Vermeire et al. GUT
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study
- (2010) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
- (2010) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
- (2010) Gary R. Lichtenstein et al. Clinical Gastroenterology and Hepatology
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
- (2010) A. Dignass et al. Journal of Crohns & Colitis
- Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases
- (2009) Michael Elliott et al. Annals of the New York Academy of Sciences
- Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9mg extended-release tablets in patients with active left-sided ulcerative colitis
- (2009) G.R. D'Haens et al. Journal of Crohns & Colitis
- Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
- (2008) Brian G. Feagan et al. Clinical Gastroenterology and Hepatology
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now